Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Astria Therapeutics (ATXS) Depreciation & Amortization (CF): 2017-2019

Historic Depreciation & Amortization (CF) for Astria Therapeutics (ATXS) over the last 3 years, with Dec 2019 value amounting to $3,000.

  • Astria Therapeutics' Depreciation & Amortization (CF) fell 62.50% to $3,000 in Q4 2019 from the same period last year, while for Dec 2019 it was $26,000, marking a year-over-year decrease of 78.15%. This contributed to the annual value of $26,000 for FY2019, which is 78.15% down from last year.
  • As of Q4 2019, Astria Therapeutics' Depreciation & Amortization (CF) stood at $3,000, which was down 62.50% from $8,000 recorded in Q3 2019.
  • Astria Therapeutics' Depreciation & Amortization (CF)'s 5-year high stood at $88,000 during Q1 2017, with a 5-year trough of $3,000 in Q4 2019.
  • Over the past 3 years, Astria Therapeutics' median Depreciation & Amortization (CF) value was $25,500 (recorded in 2018), while the average stood at $37,417.
  • In the last 5 years, Astria Therapeutics' Depreciation & Amortization (CF) crashed by 91.67% in 2018 and then soared by 33.33% in 2019.
  • Over the past 3 years, Astria Therapeutics' Depreciation & Amortization (CF) (Quarterly) stood at $67,000 in 2017, then tumbled by 88.06% to $8,000 in 2018, then plummeted by 62.50% to $3,000 in 2019.
  • Its Depreciation & Amortization (CF) stands at $3,000 for Q4 2019, versus $8,000 for Q3 2019 and $7,000 for Q2 2019.